PPLPHARMA

Piramal Pharma Limited · ISIN INE0DK501011 · Health Technology

Margin Trading Facility book for PPLPHARMA across NSE and BSE. Free to use — no signup, no paywall. All figures in ₹ crore, derived from NSE and BSE public disclosures.

Funded value
₹185 Cr
as of 23 Jul 2026
Rank in book
#200
368 days tracked
Share of book
0.13%
of the whole NSE + BSE book
Peak funded
₹227 Cr
on 07 Jul 2026
NSE
₹178 Cr
BSE
₹7 Cr
Largest single-day addition
+₹33 Cr
on 15 May 2025
Largest single-day unwind
−₹24 Cr
on 15 Jul 2025

PPLPHARMA — last 30 trading days

Combined NSE + BSE funded value, day-on-day change, share of the whole market book, and rank. Newest first.
DateCombinedDay ΔNSEBSE% of bookRank
23 Jul 2026₹185 Cr−₹11₹178₹70.13%200
22 Jul 2026₹196 Cr+₹5₹189₹70.14%181
21 Jul 2026₹191 Cr−₹14₹184₹70.13%187
20 Jul 2026₹205 Cr+₹4₹198₹70.14%161
17 Jul 2026₹202 Cr−₹15₹194₹70.14%168
16 Jul 2026₹216 Cr−₹3₹209₹70.15%150
15 Jul 2026₹220 Cr+₹2₹212₹80.15%148
14 Jul 2026₹218 Cr+₹2₹210₹70.15%148
13 Jul 2026₹215 Cr+₹1₹208₹70.15%148
10 Jul 2026₹214 Cr−₹9₹207₹70.15%148
09 Jul 2026₹223 Cr−₹3₹215₹80.16%147
08 Jul 2026₹226 Cr−₹2₹218₹80.16%144
07 Jul 2026₹227 Cr+₹2₹220₹70.16%144
06 Jul 2026₹225 Cr+₹0₹218₹70.16%147
03 Jul 2026₹224 Cr+₹10₹218₹70.16%142
02 Jul 2026₹215 Cr+₹3₹207₹80.15%147
01 Jul 2026₹212 Cr+₹1₹204₹70.15%157
30 Jun 2026₹211 Cr−₹0₹204₹70.15%157
29 Jun 2026₹211 Cr+₹3₹204₹80.15%155
25 Jun 2026₹209 Cr+₹4₹201₹70.15%157
24 Jun 2026₹204 Cr−₹0₹197₹70.15%163
23 Jun 2026₹205 Cr+₹8₹198₹70.15%162
22 Jun 2026₹196 Cr+₹3₹189₹70.14%170
19 Jun 2026₹193 Cr+₹3₹186₹70.14%174
18 Jun 2026₹190 Cr+₹9₹183₹70.14%178
17 Jun 2026₹181 Cr+₹2₹175₹60.14%190
16 Jun 2026₹179 Cr+₹6₹173₹60.13%188
15 Jun 2026₹173 Cr+₹1₹167₹60.13%197
12 Jun 2026₹172 Cr+₹4₹166₹50.13%193
11 Jun 2026₹168 Cr₹163₹50.12%204

IndiaMTF is an independent informational project. It is not a brokerage, is not affiliated with NSE, BSE or any SEBI-registered entity, and does not provide investment advice. Figures are derived from NSE and BSE public disclosures and may be revised or restated by the exchanges. Verify against the primary source before acting on anything here.